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ABSTRACT  
 
Introduction: Although hepatic encephalopathy (HE) on the background of acute on 
chronic liver failure (ACLF) is associated with high mortality rates, it is unknown 
whether this is due to increased blood-brain barrier permeability. Specific gravity of 
cerebrospinal fluid measured by CT is able to estimate blood-cerebrospinal fluid-
barrier permeability. This study aimed to assess cerebrospinal fluid specific gravity in 
acutely decompensated cirrhosis and to compare it in patients with or without ACLF 
and with or without hepatic encephalopathy.  
Method: We identified all the patients admitted for acute decompensation of cirrhosis 
who underwent a brain CT-scan. Those patients could present acute 
decompensation with or without ACLF. The presence of hepatic encephalopathy was 
noted. They were compared to a group of stable cirrhotic patients and healthy 
controls. Quantitative brain CT analysis used the Brainview software that gives the 
weight, the volume and the specific gravity of each determined brain regions. Results 
are given as median and interquartile ranges and as relative variation compared to 
the control/baseline group. 
Results: 36 patients presented an acute decompensation of cirrhosis. Among them, 
25 presented with ACLF and 11 without ACLF; 20 presented with hepatic 
encephalopathy grade>2. They were compared to 31 stable cirrhosis patients and 61 
healthy controls. Cirrhotic patients had increased cerebrospinal fluid specific gravity 
(CSF-SG) compared to healthy controls (+0.4%, p<0.0001). Cirrhotic patients with 
ACLF have decreased CSF-SG as compared to cirrhotic patients without ACLF (-
0.2%, p=0.0030) that remained higher than in healthy controls. The presence of 
hepatic encephalopathy did not modify CSF-SG (-0.09%, p=0.1757). Specific gravity 
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did not differ between different brain regions according to the presence or absence of 
either ACLF or HE. 
Conclusion: In patients with acute decompensation of cirrhosis, and those with 
ACLF, CSF specific gravity is modified compared to both stable cirrhotic patients and 
healthy controls. This pattern is observed even in the absence of hepatic 
encephalopathy suggesting that blood-CSF barrier impairment is manifest even in 
absence of overt hepatic encephalopathy. 
 
Key words: hepatic encephalopathy; brain edema; blood-brain barriers; blood-
cerebrospinal fluid-barrier; CT scan 
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INTRODUCTION 
Overt hepatic encephalopathy (HE) requiring hospital admission is a common 
complication of cirrhosis that is associated with high resource utilization and a 
significant in-hospital mortality [1,2]. HE patients have a significantly lower survival 
compared with patients without HE at all severities of liver disease [3,4]. Acute on 
chronic liver failure (ACLF) is a clinically and prognostically distinct syndrome that 
occurs in cirrhotic patients who are hospitalized with acute deterioration due to either 
known or unknown precipitating events, hepatic and/or extrahepatic organ failure and 
high short term mortality rates. Pathophysiologically, the syndrome is characterized 
by altered host response to injury. One major recent finding is that HE in patients 
displaying a diagnosis of ACLF have higher mortality compared with HE patients 
without ACLF [3].  
The mechanism underlying the pathophysiology of HE in ACLF and this susceptibility 
to increased mortality is not known. In spite of its high frequency, HE 
pathophysiology is poorly understood. Increased cerebral ammonia uptake, and its 
transformation into glutamine by the astrocytes are thought to be important 
mechanisms causing neurological symptoms [5]. However, since there is poor 
correlation between ammonia and the severity of HE, other factors could be 
implicated [6,7]. For instance, the cerebral accumulation of different substances 
besides ammonium, like amino acids (AA) [8], manganese [9], biliary salts, has been 
demonstrated in patients with cirrhosis or porto-systemic shunts. More recently, 
inflammation has been thought to contribute to the severity of HE both in animal 
models and also in humans [6,10]. Indeed, inflammation is clearly more marked in 
patients with ACLF and HE compared with those with acute decompensation but no 
ACLF with similar severities of HE, suggesting that the underlying pathophysiological 
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mechanisms may be different. Severe cerebral edema has been reported in some 
studies in cirrhotic patients with HE [11]. Indeed, death of about 5% ACLF patients is 
thought to be caused by severe cerebral edema [12]. Whether this is associated with 
blood-brain barriers dysfunction is not known.  
Brain homeostasis is of major importance to carry out the complex physiological 
functions, especially synaptic transmission. Thus, exchanges between the blood and 
the brain are tightly regulated by tight junctions on two main cellular interfaces that 
restrict the permeability: the blood-brain barrier that is located on cerebral endothelial 
cells and the blood-cerebrospinal fluid barrier (BCSFB) located on epithelial cells of 
choroid plexuses (see [13,23] for review). Even if tight junctions are expressed in the 
cerebral endothelial cells of the blood-brain barrier and on epithelial cells of choroid 
plexuses on the BCSFB, their molecular and cellular organization is very closely 
organized (see for review [13,14]). Dysfunction of these barriers have been recently 
highlighted in different neurological diseases and their dysfunction in cirrhotic 
patients, especially those with HE, has been suggested to be pathophysiologically 
relevant [11,14]. Recent studies highlighted that the BCSFB constitute a large 
surface area for exchanges, greater than previously thought, and that this barrier 
intervene in availability of drugs. Thus, MRI studies have shown that in case of 
manganese accumulation for example, this metal first accumulates in CSF as a 
transfer across the choroid plexuses before spreading to periventricular regions 
where it enter into neural cells to reach the final destination via retrograde transport 
via axons [24]. Therefore, a more precise analysis of CSF in cirrhotic patients with or 
without ACLF would be of major interest but access to CSF is difficult since these 
patients often have low platelets that render lumbar puncture a high risk procedure.  
 6 
The measurement of the specific gravity (SG), which is defined as the weight of the 
volume of an object, is a validated and reliable method to characterize any solute, 
estimate the water content of CSF or of different brain regions [15,16]. CT scanning 
and post-processing analysis by a dedicated software, Brainview (Institut Nationale 
des Télécommunications [15,17,18]), has already been used to assess SG in 
patients for the evaluation of brain edema [15,19,20]. Thus, studying CSF-SG allows 
this question to be addressed. The normal CSF-SG is between 1.007 and 1.008. 
Disease related variations of SG could be analyzed in patients that undergo a CT 
scan [20]. A decrease in CSF-SG suggests passage through the BCSFB of either a 
substances with a SG lower than that of the CSF or the passage of solute whereas 
an increase of CSF-SG suggests the passage through the BCSFB of a substances 
with a SG greater than that of the CSF. Interestingly, SG of the substances that has 
previously been shown as being present in the CSF of cirrhotic patients are well 
known and are as follows, ammonium has a SG of 0.9, bile salts a SG between 
1.010 and 1.040 and, immunoglobulins a SG of more than 1.060. 
 
Thus, the modification in the blood-CSF barrier permeability could represent a first 
step in the physiopathology of ACLF or HE, responsible for modification in the CSF 
composition and afterwards in the brain extracellular compartment.  
Therefore, the aims of this study were to assess CSF-SG in acutely decompensated 
cirrhosis and to compare it in patients with and without ACLF and with and without 
HE. 
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PATIENTS AND METHODS 
 
Patient’s selection 
We retrospectively identified all the patients admitted for acute decompensation of 
cirrhosis in two Hepatology ICUs of two tertiary care centers (Royal Free Hospital, 
London, United-Kingdom and La Pitié-Salpêtrière Hospital, Paris, France) who 
underwent a brain CT-scan between January 2013 and April 2013. Both center admit 
about 250 patients every years for acute decompensation of cirrhosis and 50% of 
these patients present ACLF and 40% present with HE. Those patients could present 
acute decompensation with or without ACLF [21] and with or without HE. Patients 
were included, provided they fulfilled the following criteria: (1) CT-scan with 
contiguous slices without interspaces; (2) no previous neurological history except HE; 
(3) no cerebral hemorrhage on CT; (4) no history of contrast medium injection within 
the last 2 weeks for analysis purpose. Patients were compared to a group of stable 
cirrhotic patients followed up in the same units who underwent brain CT-scan in their 
pre-transplant workup for hepatocellular carcinoma in order to rule out brain 
metastasis. Cirrhosis was diagnosed using a combination of clinical, biological, 
radiological, histological and anatomo-pathological features.  
 
Healthy controls 
Non-cirrhotic patients that underwent a CT-scan with contiguous slices without 
interspaces at emergency department for headaches or trauma and that were finally 
interpreted as normal were used as healthy controls. 
 
Data collection 
The following data were collected at admission: demographic data (age, gender), 
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natural history of cirrhosis (etiology, presence of ascites, previous episodes of 
bleeding, previous episodes of HE, hepatocellular carcinoma), cause of admission, 
physical examination, laboratory measurements (leukocyte and platelet count, 
prothrombin time (PT), international normalized ratio (INR), and levels of liver 
enzymes, bilirubin, creatinine, sodium, albumin and C-reactive protein (CRP)). The 
severity of cirrhosis was evaluated by the Child-Pugh score. The presence of HE and 
of ACLF was noted. The presence of HE was diagnosed as impairment in 
consciousness, or motor function in a patient with cirrhosis after exclusion of other 
causes of mental disturbance. The severity of HE was assessed by senior 
hepatologists using West-Haven score (WH). Overt HE was considered if WH was 
equal or higher than 2. To quantify organ dysfunction, the CLIF-OF score was used. 
This score derived from SOFA assess six organ systems (liver, kidneys, brain, 
coagulation, circulation, lungs) and takes in account the specificity of cirrhosis [21]. 
The presence or the absence and grade of ACLF was defined as previously 
described [22].  
 
CT-scan analysis 
CT-scans were acquired on a Philips scanner (Netherlands) in London and on a 
Siemens scanner (Germany) in Paris. Quantitative brain CT analysis was performed 
using the Brainview software (Institut National des Télécommunications) [17]. Briefly, 
this validated software [17,18] is aimed to analyze DICOM images acquired from 
cerebral CT scans by performing automatical segmentation excluding extracranial 
compartments on each slices. Interactive slice-by-slice segmentation allows to 
delineate different anatomical regions. The software renders the weight, the volume 
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and the specific gravity (SG) of the whole brain and of each individual region (right 
and left hemispheres, brainstem, cerebellum, and intraventricular CSF).  
 
Statistical analysis 
Continuous variables are expressed as median and interquartile range (IQR). 
Categorical variables are expressed as frequencies and percentages. Chi-square or 
Fisher exact test was used to compare categorical variables and ANOVA for 
continuous variables, with Tukey range test for correction. Univariate analysis was 
used to compare the variables between the different groups. In order to take in 
account the acquisition in two centers, and the possible differences in CT calibration, 
stratification according to the center was performed.  
All statistical tests were two-tailed. P values that were less than 0.05 were 
considered to indicate statistical significance. Analysis involved use of JMP v9.0 
(SAS Inst., Cary, NC).  
 
According to the French law, the approval of the local ethics committee was not 
necessary since the CTs were included in the clinical management of the patients 
and the study was retrospective. The database in which the patients were identified 
had been submitted to and approved by the French national commission for 
computerized files and liberty (CNIL, Commission Nationale de l’Informatique et des 
Liberte´s). Royal Free Hospital research ethics committee gave its approval for the 
study. 
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RESULTS 
 
Subjects  
From January 2013 to April 2013, 72 cirrhotic patients underwent a cerebral CT scan. 
Five CTs were not analyzable, thus 67 patients were finally retained for analysis. 
Overall, 36 cirrhotic patients were admitted for acute decompensation (25 presented 
with ACLF and 11 with acute decompensation without ACLF) and 31 for stable 
cirrhosis. Results were compared to that of 61 healthy controls. Baseline 
characteristics of the patients and the controls are displayed in Table 1. In patients 
with acute decompensation, 20 patients (56%) displayed overt HE (WH grade 2: 
n=12, grade 3, n=7, grade 4, n=1) and 25 (69%) displayed ACLF. 15 patients (42%) 
presented with both ACLF and HE. No patients had HE or ACLF in the stable 
cirrhotic patients. Indication for brain CT-scan differed significantly between patients 
with and without overt HE. Brain CT-scans in healthy controls were performed mainly 
because of headache.  
 
Quantitative CT analysis  
SG values did not differ between the two centers. Thus, data were analyzed together. 
 
Cirrhotic patients whether they were or not decompensated display increased CSF-
SG as compared to healthy controls 
Compared to healthy controls, cirrhotic patients had increased CSF-SG (1.01178 
[1.01014-1.01375] vs 1.00855 [1.00688-1.01045], +0.3 %, p<0.0001, respectively) 
suggesting the passage of substances with a SG greater than that of the CSF 
through the BCSFB in cirrhotic patients.  
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Acutely decompensated cirrhotic patients display a mild decrease in CSF-SG as 
compared to patients with stable cirrhosis  
Acutely decompensated cirrhotic patients compared to stable cirrhotic patients had a 
decreased CSF-SG (1.01088 [1.00922-1.01224] vs 1.01256 [1.01156-1.01458] 
respectively, -0.2%, p=0.0002) suggesting increased permeability of the BCSFB to 
either solutes or substances with a lower SG in this setting (Table 2 and Figure 1A). 
CSF-SG in acutely decompensated cirrhotic patients remained however higher than 
in healthy controls (1.01088 [1.00922-1.01224] vs 1.00855 [1.00688-1.01045], 
respectively, +0.2%, p<0.0001). 
 
Cirrhotic patients with ACLF have decreased CSF-SG as compared to cirrhotic 
patients without ACLF 
Cirrhotic patients with ACLF displayed decreased CSF-SG as compared to patients 
without ACLF (1.01036 [1.00908-1.01207] vs 1.01218 [1.01103-1.01412]   
respectively, -0.2%, p=0.0030,), suggesting increased permeability of the BCSFB to 
either solutes or substances with a lower SG in this setting (Table 3 and Figure 1B). 
 
The presence of HE does not modify the CSF-SG in cirrhotic patients. 
In cirrhotic patients, patients with HE displayed a CSF-SG of 1.01122 [1.00986-
1.01224] compared to 1.01209 [1.01024-1.01408], -0.09%, in patients without HE 
(p=0.1757) (Table 3 and Figure 1C).  
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DISCUSSION 
By using CT scanning analysis of the SG of the CSF, we found arguments in favor of 
increased permeability of the BCSFB in cirrhotic patients. Indeed, results of the 
present pilot study suggest that cirrhotic patients display alterations of the BCSFB, 
that are dependent on the severity of liver disease. Importantly, these alterations are 
influenced by the presence of ACLF, but occur even in the absence of HE. These 
results suggest that, in cirrhotic patients, BCSFB permeability to substances and 
solutes are altered.  
 
It seems that, early in cirrhosis, even in those without acute decompensation, some 
substances with a SG higher than that of the CSF, i.e. higher than 1.008, cross the 
BCSFB. Elevated levels of glutamine, glutamate, alpha ketoglutarate, bile salts and 
increased concentrations of serotonin, dopamine and AA have been reported in the 
CSF of cirrhotic patients [26–28]. According to our results in stable cirrhotic patients 
compared to healthy controls, the passage of bile salts, the SG of which ranges from 
1.010 to 1.040, into the CSF could explain the increase in CSF-SG. Indeed, bile salts 
have been shown to accumulate in these conditions [29]. Furthermore, bile salts 
have a synergistic effect with endotoxin and ammonia on the formation of brain 
edema by their action on Na-K-ATPase [30]. Several data also reported an increased 
level in both brain and CSF of tryptophan and its metabolites 5-HIAA, in patients with 
porto-systemic shunts and cirrhosis [31]. Hence, in cirrhotic patients the level of 
tryptophan in the CSF was 4-fold higher than in controls. Several AA were found to 
be elevated in the CSF in the setting of ALF [32], and animal models of cirrhosis 
displayed an increased CSF level of tryptophan [31]. In the CSF of cirrhotic patients 
without HE, a significant increase was found in nearly all amino acids, including those 
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known not to cross the blood-brain barriers readily, suggesting the presence of a 
nonspecific modification of the BCSFB permeability [28]. This could also explain the 
increase of CSF-SG in the cirrhotic patients. The passage of proteins such as IgG 
seems less probable since no major brain edema was present. The possible passage 
of some yet unknown substance or medication cannot be ruled out. Indeed, increase 
of CSF-SG is a classical finding in the administration of local anesthesics for spinal 
anaesthesia. In some pathological conditions such as seizures, increased blood 
osmolarity can induce dehydration of the brain and thus an increase its SG [33]. We 
recently showed using metabolomics that the CSF of cirrhotic patients displaying 
neurological symptoms contained the main above mentioned substances and several 
xenobiotics, i.e. drugs, that all could contribute to the modification in CSF-SG [34,35].  
 
In cirrhotic patients with HE, CSF-SG was not statistically different compared to 
cirrhotic patients without HE. This observation is somewhat surprising given that 
ammonia (SG: 0.9) has been shown to be increased in the CSF in patients with HE 
[36]. The data support the hypothesis that alterations of cerebral homeostasis occur 
even in the absence of HE, evidenced by studies showing alterations in myoinositol 
and glutamine in the brain of patients with cirrhosis with and without HE [37,38]. The 
manifestation of HE is therefore likely to be due not only to alterations of blood-brain 
barriers, but also to other interacting factors.  
 
In cirrhotic patients with ACLF, CSF-SG was decreased compared to acute 
decompensation without ACLF patients. This finding suggests again an alteration in 
BCSFB. Inflammation is the main physiopathological hallmark of ACLF. Hence, one 
hypothesis is an increased passage of solutes since BCSFB permeability to solutes, 
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is particularly influenced by inflammatory mediators such as TNF-alpha or IFN-
gamma. Our results suggest that ACLF patients present altered BCSFB even in the 
absence of HE. The significance of this observation is not clear.  It is tempting to 
hypothesize that these abnormalities may make the patient susceptible to the 
development of HE but this hypothesis will have to be confirmed in future studies.  
 
Our study has several limitations. First, it was retrospective and the diagnosis of 
ACLF and HE was retrieved in medical records. Bias could be introduced in our study 
by the fact that we considered only overt HE and not minimal HE. Since this 
retrospective design, case-mix cannot be excluded. For example, patients who 
underwent a CT-scan for another reason than HE were patients hospitalized for the 
workup of hepatocellular carcinoma, which were displayed far more severe liver 
disease than usual patients with hepatocellular carcinoma. Furthermore, we could 
include only patients that underwent CTs without interslice spaces. Last, the 
composition of substances that cross the BCSFB need further analysis of the CSF 
but lumbar puncture is rarely indicated in cirrhotic patients, and this type of study is 
probably not ethically possible. This study provides the novel data describing 
changes in CSF content in cirrhotic patients.  
 
In conclusion, our study describes for the first time that CSF-SG is modified in 
cirrhotic patients, both with and without HE suggesting altered BCSFB permeability to 
substances and solutes. Patients with ACLF display further alterations of BCSFB, 
which may indicate their susceptibility to HE. The observation that abnormalities in 
the BCSFB are manifest even in the absence of overt HE may have important clinical 
and pathophysiological implications. 
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Table 1: Baseline characteristics of the patients and the controls.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are mean  SD or number (%). 
 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive 
protein; HE, hepatic encephalopathy; INR, international standardized ratio; MELD, Model for End-
Stage Liver Disease; PTT, prothrombin time 
  
Acute decompensation 
of cirrhosis  
  
n = 36 
 
Stable cirrhotic patients 
 
 
n=31 
 
 
Healthy controls 
 
 
n = 61 
 
p value 
Age, years 55 [47-65] 59 [48-63] 64 [46-78] 0.3347 
Male gender (%) 23 (64%) 26 (84%) 39 (64%) 0.1134 
Etiology of cirrhosis      
Viral  4 (11%) 0 (0%) -  
Alcohol consumption 22 (61%) 22 (72%) -  
Other 10 (28%) 8 (25%) -  
Ascites 9 (56%) 0 (0%) - < 0.0001 
ACLF 25 (69%) 0 (0%) - < 0.0001 
Hepatocelullar 
carcinoma 
3 (8%) 31 (100%) - < 0.0001 
Acute alcoholic 
hepatitis 
6 (38%) 0 (0%) - 0.0003 
TIPS 7 (44%) - -  
Asterixis 11 (69%) 0 (0%) - < 0.0001 
PTT (%) 32 [31-44] 64 [46-76] NA 0.0001 
INR 2.0 [1.6-2.5] 1.4 [1.2-2.0] NA 0.0081 
Leukocyte count 
(/mm3) 
9 625 [6 683-16 848] 4 900 [3 450-7 800] 10 030 [7140-12 920] 0.0055 
Platelet count (/mm3) 81 500 [50 500-125 750] 67 000 [47 500-88 500] NA 0.3442 
Creatinine level (mg/dL) 0.94 [0.63-1.35] 0.74 [0.67-0.89] NA 0.1309 
Albumin level (g/L) 25 [22-31] 34 [31-40] NA 0.0014 
Bilirubin level (mg/dL)  5.1 [1.7-8.9] 1.1 [0.8-1.9] NA 0.0013 
AST level (U/L) 82 [60-177] 67 [46-82] NA 0.0931 
ALT level (U/L) 48 [25-80] 45 [30-55] NA 0.3700 
Sodium level (mmol/L) 139 [133-145] 139 [134-142] NA 0.3339 
CRP level (mg/l) 20.5 [6.3-48.3] 7.5 [4.0-14.0] NA 0.0203 
Child-Pugh score     
A 2 (6%) 26 (83%) -  
B 2 (6%) 5 (17%) -  
C 32 (88%) 0 -  
CLIF-SOFA score 11 [8-12] NA -  
Hepatic 
encephalopathy 
20 (56%) 0 (0%)  < 0.0001 
West-Haven score    < 0.0001 
0 4 (11%) 31 (100%) -  
1 12 (33%) - -  
2 12 (33%) - -  
3 7 (19%) - -  
4 1 (3%) - -  
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Table 2: Specific gravity of different brain regions according to the presence or 
not of cirrhosis and the presence or not of acute decompensation of cirrhosis. 
 
 
 Healthy controls 
n = 61 
Stable cirrhotic patients 
n = 31 
Acute decompensation of  
cirrhosis 
n = 36 
p-value 
CSF 1.00855 [1.00688-1.01045] 1.01256 [1.01156-1.01450] 1.01088 [1.00922-1.01224] < 0.0001 
Relative 
difference (%) 
na + 0.4 % + 0.2 %  
Whole brain 1.02934 [1.02812-1.03108] 1.02920 [1.02792-1.03023] 1.02844 [1.02708-1.02967] 0.0329 
Relative 
difference (%) 
na - 0.01 % - 0.08 %  
Hemispheres 1.02903 [1.02753-1.03058] 1.02885 [1.02766-1.02965] 1.02793 [1.02657-1.02940] 0.0462 
Relative 
difference (%) 
na - 0.01 % - 0.1 %  
Brainstem 1.02138 [1.02080-1.02231] 1.02534 [1.02373-1.02593] 1.02448 [1.02290-1.02580] < 0.0001 
Relative 
difference (%) 
na + 0.4 % + 0.3 %  
Cerebellum 1.03502 [1.03310-1.03619] 1.03297 [1.03081-1.03360] 1.03201 [1.03114-1.03430] < 0.0001 
Relative 
difference (%) 
na - 0.3 % - 0.3 %  
 
Relative differences are given compared to controls.  
Abbreviation: CSF, cerebrospinal fluid; na: not applicabla. 
 
 
Table 3: Specific gravity of different brain regions according to the presence or 
absence of ACLF and HE.  
 
 Hepatic encephalopathy  ACLF  
 No 
n = 47 
Yes 
n = 20 
p-value No 
n = 42 
Yes 
n = 25 
p-value 
CSF 1.01209 [1.01024-
1.01408] 
1.01122 [1.00986-
1.01224] 
0.1757 1.01218 [1.01103-
1.01412] 
1.01036 [1.00908-
1.01207] 
0.0030 
Relative 
difference (%) 
Na - 0.09 %  na - 0.2 %  
Whole brain 1.02940 [1.02782-
1.03023] 
1.02854 [1.02718-
1.02966] 
0.4353 1.02912 [1.02781-
1.03014] 
1.02866 [1.02669-
1.02975] 
0.1450 
Relative 
difference (%) 
na - 0.08 %  na - 0.05 %  
Hemispheres 1.02871 [1.02737-
1.02968] 
1.02812 [1.02663-
1.02942] 
0.3946 1.02873 [1.02747-
1.02965] 
1.02838 [1.02613-
1.02960] 
0.1255 
Relative 
difference (%) 
na - 0.06%  na - 0.03 %  
Brainstem 1.02494 [1.02342-
1.02571] 
1.02487 [1.02305-
1.02630] 
0.7815 1.02515 [1.02344-
1.02572] 
1.02479 [1.02292-
1.02618] 
0.6563 
Relative 
difference (%) 
na - 0.01%  na - 0.04 %  
Cerebellum 1.03266 [1.03083-
1.03360] 
1.03256 [1.03130-
1.03455] 
0.3952 1.03268 [1.03079-
1.03359] 
1.03226 [1.03122-
1.03443] 
0.6648 
Relative 
difference (%) 
na - 0.01%  na - 0.04 %  
 
Relative differences are given compared to controls.  
Abbreviation: ACLF, acute on chronic liver failure ; CSF, cerebrospinal fluid. 
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FIGURES LEGENDS 
 
Figure 1: CSF specific gravity according to the presence or not of cirrhosis, the 
presence or not of acute decompensation of cirrhosis, of ACLF and HE. 
 
A, CSF SG according to the presence or not of cirrhosis and the presence or not of acute 
decompensation of cirrhosis; B, CSF SG according to the presence or not of ACLF; C, CSF SG 
according to the presence or not of HE.  
 
Supplemental figure: Specific gravity of different brain regions according to 
the presence or not of cirrhosis and the presence or not of acute 
decompensation of cirrhosis. 
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